Singapore, Aug. 23 -- Voronoi, drug discovery and development biotech company in Korea has announced that it has, after an extensive evaluation process, selected CDD Vault as its platform of choice to manage its drug discovery data and collaborative projects. Voronoi's chemistry and biology data, including chemical structures and assay data will be stored, managed and analyzed in CDD Vault developed by Collaborative Drug Discovery.

Voronoi through its divisions Voronoi Bio and B2S Bio has implemented a new streamlined drug discovery process. It includes molecular modelling and Target Protein Degrader (TPD) technology to identify new targets as well as new drug candidates. Voronoi's research efforts are focused on Alzheimer's disease, str...